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A B S T R A C T   
Health decision models are the only available tools designed to consider the lifetime natural history of human 
papillomavirus (HPV) infection and pathogenesis of cervical cancer, and the estimated long-term impact of 
preventive interventions. Yet health decision modeling results are often considered a lesser form of scientific 
evidence due to the inherent needs to rely on imperfect data and make numerous assumptions and extrapolations 
regarding complex processes. We propose a new health decision modeling framework that de-emphasizes 
cytologic-colposcopic-histologic diagnoses due to their subjectivity and lack of reproducibility, relying instead 
on HPV type and duration of infection as the major determinants of subsequent transition probabilities. We posit 
that the new model health states (normal, carcinogenic HPV infection, precancer, cancer) and corollary transi-
tions are universal, but that the probabilities of transitioning between states may vary by population. Evidence for 
this variability in host response to HPV infections can be inferred from HPV prevalence patterns in different 
regions across the lifespan, and might be linked to different average population levels of immunologic control of 
HPV infections. By prioritizing direct estimation of model transition probabilities from longitudinal data (and 
limiting reliance on model-fitting techniques that may propagate error when applied to multiple transitions), we 
aim to reduce the number of assumptions for greater transparency and reliability. We propose this new micro-
simulation model for critique and discussion, hoping to contribute to models that maximally inform efficient 
strategies towards global cervical cancer elimination.   
1. Introduction 
Understanding of human papillomavirus (HPV) and the necessary 
steps in cervical carcinogenesis has led to effective prevention methods. 
Yet the absolute number of cases of cervical cancer is rising worldwide 
due to lack of resources and aging of lower-resource populations. More 
than a half-million cases and quarter-million deaths still occur each 
year— almost 90% in low- and middle-income countries (LMIC).(Bray 
et al., 2018) Prophylactic HPV vaccination can protect against infection 
with the carcinogenic HPV types that cause between 70% and 90% of 
cervical cancers,(Guan et al., 2012) but only ~10% of girls in LMIC have 
been vaccinated.(Bruni et al., 2020) Women past the target age of 
vaccination can be protected against cancer through detection and 
treatment of cervical cancer precursor lesions (“precancer”), but less 
than 20% in LMIC have ever been screened in effective programs. 
(Gakidou et al., 2008) 
Health decision models have been used extensively to inform 
decision-making related to cervical cancer control policies globally. 
(Canfell et al., 2012) In May 2018, the Director-General of the World 
Health Organization (WHO) announced a global call to action towards 
the elimination of cervical cancer (World Health Organization, 2018). 
Health decision modeling based on highly optimistic benchmarks for 
vaccine uptake and screening program coverage was presented in sup-
port of this call to action, setting interim prevention implementation 
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targets to be achieved by 2030 in order to reach the elimination goal 
over the coming century.(Brisson et al., 2020) However, with the cur-
rent COVID-19 pandemic, the 2030 targets of the call to action are very 
unlikely to be realized. Cervical cancer is likely to continue to dispro-
portionately kill women in LMIC. We might already need to adjust ap-
proaches and expectations. 
Health decision analyses that guide choices between cervical cancer 
prevention strategic alternatives estimate the costs and benefits to 
women over the long-term, extending past the limits of empirical studies 
that cannot fully compare all relevant strategies.(Goldie et al., 2006) 
Randomized clinical trials and rigorous longitudinal cohort studies are 
ideal to evaluate preventive methods over the short-term. However, 
given the typically long interval between acquisition of HPV infection 
and cancer, health decision models are the only available tools designed to 
consider the lifetime natural history of HPV and pathogenesis of cervical 
cancer, and the estimated long-term impact of prevention strategies. 
Particularly in LMIC, policy makers increasingly rely on health decision 
model projections of health impact and cost-effectiveness for decision 
making. 
Given the essential role of cost-effectiveness analyses on global cer-
vical cancer prevention policy, it is imperative that the health decision 
models reflect advancing knowledge of HPV natural history and prove to 
be trustworthy.(Egger et al., 2017) Due to inherent complexity and 
requisite assumptions, models are often perceived as “black boxes” that 
lack transparency; findings are not easily reproduced independently. 
(Frommert, 2015) To the degree that there are unknowns and we must 
estimate (with possible error) the model inputs for a substantial pro-
portion of the details, the final answers are prone to change. For 
example, the modeling efforts that underlie the current WHO call to 
action(Brisson et al., 2020) project trends over nearly a century and do 
not consider novel prevention strategies. Different models may yield 
qualitatively different results, leaving decision makers in a quandary 
regarding which (if any) are accurate.(Burger et al., 2020; Kuntz et al., 
2011; Pignone and Ransohoff, 2011) Comparative modeling exercises 
must be undertaken not only with the goal of understanding modeling 
differences, but with an openness to revisiting fundamental model as-
sumptions when inconsistencies are revealed.(Kuntz et al., 2011; 
Pignone and Ransohoff, 2011) 
We acknowledge the enormity of effort involved in revising health 
decision models. Faced with evolving natural history data, modelers 
must decide when incremental improvements will be sufficient and 
when a more substantive revision is necessary. Existing models of HPV 
and cervical pathogenesis are in different stages of evolution. However, 
at this critical juncture, we have advanced scientific understanding of 
cervical cancer development, necessary precursor states, the perfor-
mance of leading prevention methods, and the effectiveness of 
combining prevention methods into implementable strategies.(Schiff-
man et al., 2016) To evaluate these strategies reliably and accurately, 
the models need greater fidelity to the natural history than they 
currently have. 
In this manuscript, we propose an HPV type-based framework for a 
new set of microsimulation models that we are developing for evalua-
tion of novel prevention strategies. We posit that the proposed model 
health states are universal, but that the probabilities of transitioning 
between states may vary by population as a result of differences in host 
behavior and immunologic response; we present evidence in support of 
this hypothesis and describe ongoing work to further evaluate it. By 
explicitly showing how existing models differ from the proposed 
framework, we aim to foster discussion and further refinement of cer-
vical cancer microsimulation models, as well as scientific consensus in 
health decisions related to cervical cancer prevention and control. 
2. Overview of state-transition modeling 
The steps for building and applying health decision models for cer-
vical cancer control are presented (Table 1). Of these, the first— 
building and testing a model— is the most fundamental step to projec-
ting accurate results. Below we present our methodologic approach to 
building a new state-transition model, in which we identify necessary 
model health states; define corollary transitions between health states; 
define variables that modify transition probabilities; directly estimate 
transition probabilities; and identify highly uncertain transition 
probabilities. 
The objective for the proposed state-transition model is to project 
costs, clinical events, and health outcomes over an extended time period 
(e.g., lifetime) of a large theoretical cohort, which can be done (for 
example) through a technical process called microsimulation (Fig. 1). 
(Rutter et al., 2011) 
Table 1 
Step-by-step health decision analysis for cervical cancer control.  
Step Components of a state-transition model 
1. Build and test a model: a. Understand the etiology of cervical 
cancer. 
b. Identify the necessary intermediate states 
leading from a normal cervix to cancer. 
c. Define the corollary transitions between 
the causal states. 
d. Define population- and individual-level 
variables that meaningfully modify the 
transition. 
e. Directly estimate transition probabilities 
from longitudinal data in a representative 
population and reckon how confident we 
are of each transition probability. 
f. Identify uncertain transition probabilities 
that cannot be directly estimated. 
g. Calibrate uncertain transition 
probabilities (when data are lacking) using 
epidemiologic data targets from a 
population of interest (e.g., to produce 
realistic matches to empirical type- and age- 
specific prevalence of HPV and precancer; 
cervical cancer incidence). 
h. Validate the state-transition model to 
determine adequacy of model fit to data 
from different, independent populations 
that were not used to derive transition 
probabilities.   
2. Estimate intervention impact (costs 
and health outcomes): 
a. Identify the available and soon-to-be- 
available prevention methods. 
b. Determine population- and individual- 
level variables that meaningfully modify 
performance of the prevention methods. 
c. Directly estimate the performance of 
prevention methods (i.e., HPV vaccination; 
screening; treatment of precancer) based on 
where each interrupts the causal pathway. 
d. Anticipate likely combinations of the 
prevention methods into alternative 
strategies. 
e. Measure effective coverage and costs of 
strategies specific to different regions.   
3. Perform the health decision modeling 
analysis and compare alternative 
strategies. 
a. Run the natural history model to project 
cost and health outcomes in the absence of 
any intervention. 
b. Simulate each prevention strategy to 
project cost and health outcomes. 
c. Compare strategies incrementally, 
eliminating strategies that are more costly 
and less effective than other strategies (i.e., 
strong dominance) or less costly and less 
cost-effective than more effective strategies 
(i.e., extended dominance). 
d. Perform extensive scenario and 
sensitivity analysis on uncertain factors.  
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3. Identify necessary model health states: The multi-stage causal 
pathway to cervical cancer 
The fundamental natural history pathway includes the following 
necessary and reliably measured stages/states in the development of 
cervical cancer: 1) infection with a specific type of carcinogenic or 
“high-risk” (hr) HPV; 2) precancer, which we define as a persistent, 
transforming HPV infection associated with lesions at a high likelihood 
of invasion if left untreated; and 3) invasive cervical cancer. Both 
“precancer” and “cancer” are divided into predominant squamous 
versus less common glandular pathways (Fig. 2).(Schiffman and Went-
zensen, 2013) These health states are thought to apply to all settings, 
and will be stratified by HPV type. 
4. Define corollary transitions between health states on the 
causal pathway 
Just as the causal states are the same across settings, so are the 
corollary transitions (i.e., the forward and backward “steps” between 
health states): appearance of hrHPV types; viral disappearance versus 
Fig. 1. Microsimulation of HPV infection and cervical carcinogenesis: Translating the molecular pathogenesis of HPV to health decision modeling. 
Cervical cancer incidence and mortality in a theoretical cohort is the summation of individual women’s lifetime experiences with each of the carcinogenic or “high- 
risk” (hr) HPV types. Over time, a woman’s cervix is exposed (or not) to each of the hrHPV types. She reacts to each type independently. The worst viral outcome 
measured at a given moment defines the woman’s health state. She might have cleared 10 types previously but if one is present at the time of measurement, she is 
“infected”. If any type persists and a precancer develops, she has “precancer”. If any precancer invades, the woman has incident cancer. Outcomes are aggregated 
over the entire cohort (a “bottom-up” approach) over time to estimate the long-term population impact and cost-effectiveness of different scenarios. 
The proposed microsimulation model represents the summation of an individual woman’s experience with each HPV type (or group of types) in the cervix at any 
given month. The model begins tracking a theoretical cohort of girls prior to sexual initiation (e.g., age 9 years) on a monthly basis. Upon entering the model, all 
females in the cohort have a normal cervix (blue) (left). While HPV exposures do not necessarily happen concurrently, they are likely to happen soon after the woman 
becomes sexually active (orange) (middle). Outcomes for individual women are then aggregated over the entire theoretical cohort to project population-level 
outcomes. With time, most infections clear but some persist, increasing the risk of progression to precancer (green) (right) which, if untreated, may invade. The 
health decision modeling framework categorizes a woman by the status of her worst clone or lesion associated with each HPV type at a given time. In the example at 
right, the woman would be classified as having HPV-16 associated squamous precancer and an HPV-31 associated squamous precancer, but the model would not keep 
track of the multiple clones associated with each type. By tracking the worst clone or lesion for a given HPV type, the model aggregates information at the level of the 
infection, then the level of the woman, and then the level of the population. Women in the theoretical cohort can die of cervical cancer or of other causes (gray). 
Photograph from van der Marel, MD, Quint WGV, Schiffman M, et al. Molecular mapping of high-grade cervical intraepithelial neoplasia shows etiological domi-
nance of HPV16. International Journal of Cancer 2012;131:E946-E953. Used with permission from John Wiley & Sons, Inc. (For interpretation of the references to 
colour in this figure legend, the reader is referred to the web version of this article.) 
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persistence; progression to precancer; and invasion.(Schiffman and 
Wentzensen, 2013) Women initially transition from a normal cervix to 
an HPV-infected state (with one or more infections) based on sexual 
behavior patterns, which change with age; peak incidence for all HPV 
types typically follows soon after age at sexual initiation.(Wellings et al., 
2006) Women then face probabilities of viral clearance, or, given viral 
persistence (i.e., the absence of clearance), progression to the precancer 
state. Clearance is thought to represent cell-mediated immune sup-
pression of the type-specific infection, which is either eliminated or kept 
in an undetectable “latent” state that may reappear later due to tem-
porary weakening of immune surveillance or age-related “immune 
senescence”(Hammer et al., 2019); we thus refer to viral “appearance” 
(instead of “acquisition”) and “disappearance” (instead of “clearance”) 
to acknowledge the limitations of existing measurement assays and the 
potential for reactivation of latent infections. Precancer occurs when a 
hrHPV infection that is primarily a productive infection (i.e., producing 
more viral particles) becomes instead a transforming infection (i.e., 
associated clone of cells with severe disruption of cellular growth and 
differentiation controls).(Doorbar et al., 2012) Regression of precancer 
through cell-mediated immune control is still possible, but much less 
likely than the control of earlier productive infections. Although inva-
sion can occur quickly in unfortunate, but rare occurrences, precancers 
typically grow circumferentially for years, if not decades, before 
acquiring an invasive phenotype. 
5. Define variables that modify transition probabilities 
5.1. HPV genotype 
The transitions to precancer and cancer are influenced mainly by 
HPV genotype. HPV16 poses a uniquely elevated risk of precancer and 
cancer. Other hrHPV types fall into 3 distinct risk groups: 1) HPV18 and 
HPV45 are not particularly elevated in squamous precancer but produce 
a heightened risk of squamous cancer, as well as rarer glandular pre-
cancer and adenocarcinoma(Guan et al., 2012; Stoler et al., 2019); 2) 
HPV31, HPV33, HPV35,1 HPV52, and HPV58 are genetically related to 
HPV16 and can be considered an intermediate risk group; 3) less risky 
types of HPV have carcinogenic potential but, in fact, rarely cause 
invasive cancer; these include HPV39, HPV51, HPV56, HPV59, and 
HPV68.(Demarco et al., 2020; Guan et al., 2012) Health states in the 
new natural history model will be stratified as follows: HPV16, HPV18, 
HPV45, HPV31, HPV33, HPV35,(Pinheiro et al., 2020) HPV52, and 
HPV58 (IARC Group 1, carcinogenic to humans)(International Agency 
for Research on Cancer, 2009) have enough supportive data to estimate 
type-specific risks of transition between the health states; with rare 
cancer outcomes, HPV39, HPV51, HPV56, and HPV59 (IARC Group 1), 
and HPV68 (IARC Group 2A, probably carcinogenic to humans)(Inter-
national Agency for Research on Cancer, 2009) are pooled into a single 
stratum called “other hrHPV types”; and the many non-carcinogenic 
“low-risk” (lr) types are also pooled into two strata including types 
classified into IARC Group 2B (possibly carcinogenic to humans; in-
cludes HPV26, HPV53, HPV56, HPV66, HPV67, HPV70, HPV73, 
HPV82, HPV30, HPV34, HPV69, HPV85, HPV97) and IARC Group 3 
(not classifiable; includes condyloma-associated HPV6 and HPV11 and 
common lr types like HPV61 and HPV72).(Clifford et al., 2003; Inter-
national Agency for Research on Cancer, 2009) While lrHPV infections 
only rarely cause true precancer or cancer,(Guimera et al., 2013) we will 
include these in the natural history model because they can cause false 
positive results on hrHPV assays or contribute to “look-alike” lesions 
resembling precancer when screening interventions are modeled; mis-
classifying them as high-risk tends to lead to higher costs and 
overtreatment. 
5.2. Time since infection 
The duration of detectable infection is the main determinant of HPV 
clearance.(Demarco et al., 2020) In the absence of progression to pre-
cancer, the different HPV types tend to disappear following the same 
exponential curve (rapid initial clearance that plateaus by three years). 
(Demarco et al., 2020; Plummer et al., 2007) The longer an infection 
Fig. 2. New health decision model schematic: Universal natural history of cervical carcinogenesis. 
Each box represents a necessary stage, or health state, on the path to cervical cancer, including acquisition of a carcinogenic, “high-risk” HPV infection; progression of 
a persistent hrHPV infection to precancer (defined as persistent lesions with a high likelihood of invasion if left untreated); and invasion to cervical cancer. Each 
arrow represents the risk of transitioning between stages. Appearance— the risk of transitioning from Normal cervix to HPV infection— may include new acquisition 
of a particular genotype, re-infection with the same genotype, or reactivation of a latent infection. Disappearance— the risk of transitioning from HPV infection to 
Normal cervix— refers to the shift from a would-be detectable infection to non-detectable by a clinical HPV DNA assay, whether attributable to complete viral 
clearance or viral latency. The model distinguishes progression to squamous precancer (which may transition to squamous cell carcinoma [SCC]) from progression to 
glandular precancer (which may transition to adenocarcinoma [ADC]). Precancer occurs when a hrHPV infection that is primarily a productive infection (i.e., 
producing more viral particles) becomes instead an abortive transforming infection (i.e., associated clone of cells with severe disruption of cellular growth and 
differentiation controls, decreased programmed cell death [apoptosis] and increased genetic mutability). Regression of precancer through immune recognition and 
cell-mediated immune control is still possible, but much less likely than the control of earlier productive infections. The probability of invasion of a precancer is a 
function of time and the accumulation of genetic changes needed to overcome the coded cellular safeguards against growth inward into the cervical stroma across the 
epithelial basement membrane. Although invasion can occur quickly in unfortunate, but rare occurrences, precancers typically grow circumferentially within the 
epithelial layer for years if not decades before acquiring an invasive phenotype. Multiple precancers can occur on a cervix. If any invades, cancer results. 
1 HPV35 appears to be more prevalent in cancers among women of African 
descent. The differential natural history of HPV35 across racial groups is still 
being explored. 
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persists as a detectable infection using clinically validated assays, the 
greater the likelihood of continued persistence, which is independent of 
other types present and highly linked to progression to precancer. (Ho 
et al., 1998; Demarco et al., 2020; Plummer et al., 2007; Rodriguez et al., 
2010) The probability of invasion of a precancer is a function of time and 
the accumulation of mutations.(Doorbar et al., 2012) 
5.3. Host response to HPV: Hypothesized differences in cell-mediated 
immune responses at the population level 
The probabilities of transitioning between states show variability not 
fully acknowledged in current models, as signaled by the differences in 
HPV prevalence patterns across the lifespan linked to different levels of 
immunologic control of HPV infections. At least three distinct natural 
history patterns are observed globally (Fig. 3), and may require separate 
health decision models with different transition probabilities: 1) 
immunocompetent populations are typically characterized by uniformly 
low rates of HPV across the lifespan or, more often, declining HPV 
prevalence with age, low prevalence in mid-adult ages where screening 
is optimal, and often a minor secondary uptick at older ages (henceforth 
referred to as the Lower HPV Prevalence Model); 2) partially immuno-
deficient populations without HIV (e.g., those affected by chronic par-
asitoses in some lower-resource areas) show stable or even increasing, 
moderate HPV prevalence at mid-adult ages (Higher HPV Prevalence 
Fig. 3. Global HPV prevalence patterns. 
There are at least three distinct HPV natural history patterns that are observed globally, likely linked to different levels of immunologic control of HPV infections: a) 
immunocompetent populations are characterized by lower HPV prevalence in mid-adult women between the ages of 30 and 49 years, when screening is optimal; this 
pattern is characteristic of the Americas, Europe, and parts of Asia and the Middle East/Northern Africa as exemplified by the graphs for Colombia, the Netherlands, 
Thailand, and Algeria; b) partially immunodeficient populations that do not have a high burden of HIV but appear to have reduced cell-mediated immunity (for 
instance, due to chronic parasitoses) show higher HPV prevalence at optimal screening ages; this pattern is characteristic particularly in sub-Saharan Africa as 
exemplified by the graphs for Guinea, Mongolia, and Nigeria; and c) HIV-infected women, with pronounced immunodeficiency in controlling HPV infections, leading 
to continuous high prevalence across screening ages, as exemplified by the graph for Nigeria WLHIV (note different y-axis scale). The graphs display the prevalence of 
any hrHPV (green lines) and HPV16/18 (red lines). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of 
this article.) 
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Model); and 3) HIV-infected populations have pronounced immunode-
ficiency in controlling HPV infections, leading to continuous high 
prevalence across ages (HIV Model). While there is robust evidence 
supporting the need for an HIV model, it is not yet clear whether distinct 
models will be needed to reflect Lower and Higher HPV prevalence 
settings. 
Fig. 3. (continued). 
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6. Directly estimate transition probabilities from representative 
populations 
We hypothesize that each of the observed HPV prevalence patterns 
(i.e., Lower HPV Prevalence, Higher HPV Prevalence, and HIV) requires 
its own natural history model with different underlying transition risks. 
We reason that population differences in rates of HPV appearance and/ 
or disappearance drive the differences between these prevalence curves, 
and may be attributable to viral-host interactions— particularly cell- 
mediated immunity, which may vary by setting. 
6.1. The Lower HPV Prevalence Model 
The Lower HPV Prevalence Model characterizes most higher- 
resource populations in the Americas, Europe, and Oceania,(Bruni 
et al., 2010) with HPV prevalence that peaks soon after sexual initiation 
and declines with age (or, in some countries in Asia, the Middle East, and 
North Africa, remains low throughout the lifespan, likely as a result of 
reduced sexual transmission).(Wellings et al., 2006) A slight rebound 
around menopause may be attributed to immune senescence (i.e., 
weakening of the HPV-suppressive cell-mediated immune response due 
to age).(Gravitt, 2011) Based on data from screened populations with 
this HPV prevalence pattern, precancer prevalence requires a period of 
lesional growth in order to be diagnosed, and therefore peaks several 
years after the initial rise in HPV prevalence, although the exact moment 
of progression on the molecular level to a clone of transformed cells is 
earlier and not observable. Cancer incidence typically peaks or plateaus 
many years later.(Plummer et al., 2012) 
Of the three models, data are most abundant to inform transitions in 
the Lower HPV Prevalence Model, as most longitudinal studies of HPV 
infection occur in populations characterized by this pattern. Large NCI- 
funded data sources allowing for direct estimation of appearance, 
disappearance, and progression in Lower HPV Prevalence settings 
include the National Cancer Institute/Kaiser Permanente Northern 
California Persistence and Progression (NCI/KPNC PaP) study(Castle 
et al., 2011), the Guanacaste Natural History Study,(Bratti et al., 2004) 
the control arm of the Costa Rica Vaccine Trial and Long-Term Fol-
low-Up Study,(Gonzalez et al., 2015) and the ASCUS-LSIL Triage Study 
(ALTS).(Schiffman and Solomon, 2003) We would welcome additional 
collaborations to confirm portability of our estimates. 
6.2. The Higher HPV Prevalence Model 
Compared to the Lower HPV Prevalence Model, the Higher HPV 
Prevalence Model is characterized by a lesser decline in HPV prevalence 
as women age.(Bruni et al., 2010) Meta-analytic data suggest that this 
HPV prevalence curve is observed in some equatorial populations in 
Africa and Central and South America, and does not appear to be solely 
attributable to HIV burden as it occurs even in populations with a low 
burden of HIV.(Adebamowo et al., 2017; Gage et al., 2012) This 
continuously high burden of HPV prior to menopause may be due to 
environmental conditions that lead to a compromised immune response, 
including chronic parasitosis or helminth infestation.(Gravitt et al., 
2016) 
An alternative explanation of the HPV prevalence patterns might be 
that the presence (absence) of screening and treatment programs— not 
altered natural history transitions— lead to lower (higher) hrHPV 
prevalence in mid-adult women. Data from the NCI/Kaiser Permanente 
Northern California cohort suggest that among women under age 25 
years, the cumulative risk of CIN2+ over 16 years of follow-up is 
approximately 10% (unpublished data); if treatment also results in 
resolution of the hrHPV infection, this could partially explain the very 
low prevalence in mid-adult women in Lower HPV Prevalence settings 
with organized programs. The KPNC population is very well-screened 
(the cumulative risk of colposcopy in the same age group reaches 
approximately 35% over 16 years), and it is unclear how many of the 
lesions in young women would regress spontaneously within a short 
timespan. In Higher HPV Prevalence settings, hrHPV prevalence re-
mains high among mid-adult women with normal cytology (Supple-
mental Fig. 1). It is unclear whether this is due to different patterns of 
sexual behavior (male and/or female) across settings. 
We hypothesize that impairment of cell-mediated immunity may 
lead to reduced HPV clearance, thus contributing to sustained HPV 
prevalence. The only way to test whether there are, in fact, different 
transition probabilities by population is through analysis of prospective 
data; we and others are in the process of analyzing data from the ACCME 
cohort (Nigeria)(Adebamowo et al., 2017) and the CONCEPT cohort 
(Tanzania). More longitudinal data from high-prevalence settings would 
be welcome (particularly from studies in which multiple biopsies are 
routinely collected), and will inform decisions about whether distinct 
Lower and Higher HPV Prevalence models are necessary. 
6.3. The HIV Model 
The HIV Model represents populations of women living with HIV 
(WLHIV), who experience a profound and sustained loss of effective HPV 
control. HPV prevalence remains very high across all ages, due to the 
increased risk of acquiring HPV and reduced HPV disappearance asso-
ciated with HIV and declining CD4+ cell count.(Liu et al., 2018; 
Safaeian et al., 2008; Strickler et al., 2005) Relative to immunocompe-
tent women, WLHIV appear to have an increased risk of HPV persis-
tence, precancer, and cancer that is associated with low CD4+ count, 
(Abraham et al., 2013; Dhokotera et al., 2019; Liu et al., 2018) but it is 
unclear how much of the increase in cancer is primarily attributable to 
their higher burden of persistent HPV and associated precancers, versus 
the extent to which WLHIV with precancer may also be at greater risk of 
invasion (per precancerous lesion). HIV infection is thought to have less 
of an impact on the transition to cancer, as invasion depends upon 
accumulation of mutations rather than immune control. Antiretroviral 
therapy (ART) has led to significant life expectancy gains, but it does not 
appear to correct fully the deficient HPV control and viral persistence 
over time.(Liu et al., 2018; Minkoff et al., 2001) Further data are needed 
on HPV type- and duration-dependent disappearance and progression 
risks in order to clarify how natural history transitions are modified by 
HIV and ART status. Because the natural history of HPV is so altered in 
WLHIV, the HIV model deserves separate consideration beyond the 
scope of this paper. 
7. Identify uncertain transitions that cannot be directly 
estimated 
Natural history transitions that remain uncertain across all three 
natural history models include 1) the risk of HPV type-specific reap-
pearance; 2) the risk of progression to precancer following HPV type- 
specific reappearance; and 3) the risk of invasion. Resolution of these 
uncertainties based on direct observation is unlikely, due to limitations 
of current measurement tools, the inability to follow individual women 
over the lifespan, and the obvious ethical reasons against observing the 
transition from precancer to cancer without intervention. Below we 
summarize the limited evidence regarding these uncertain transitions, 
and the assumptions we make within the proposed modeling framework. 
7.1. The risk of HPV type-specific reappearance and subsequent 
progression to precancer 
We cannot discern the underlying cause for a woman’s shift from 
HPV-negative to HPV-positive (i.e., appearance versus reappearance) in 
the absence of genetic analysis of HPV variants from samples obtained 
from the time of first infection— which can determine whether an 
infection is genetically identical to a woman’s initial type-specific 
infection, or a distinct infection. Evidence for viral latency and subse-
quent reactivation has been provided by epidemiologic studies in which 
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newly detected HPV infections were found in older women who reported 
no new sexual partners during the interval between negative and posi-
tive HPV tests.(Gonzalez et al., 2010; Paul et al., 2020) The hypothesized 
mechanism for viral latency involves maintenance of the viral genome in 
basal epithelial cells without viral shedding or evidence of clinical dis-
ease.(Doorbar, 2018; Hammer et al., 2019) Age-related immune senes-
cence may trigger reactivation and subsequently, redetection. 
Counteracting this potential for type-specific reappearance following 
an initial infection, some women develop systemic, type-specific anti-
bodies that may protect against acquisition of future infections with the 
same type.(Beachler et al., 2016; Rosillon et al., 2019; Safaeian et al., 
2018) However, it is not clear what proportion of women experience a 
protective level or how long protection may last following seroconver-
sion, and measurement is further complicated by the differential sensi-
tivity of type-specific serology assays. 
From a modeling perspective, the underlying cause of type-specific 
reappearance– whether acquisition of a new infection or reactivation 
of a prior one– only needs to be specified if 1) there is a difference in 
subsequent risk of progression to precancer; or 2) for evaluations of 
vaccination, the vaccine has differential effectiveness against new 
acquisition versus reactivation. We hypothesize that reactivated in-
fections in older women behave similarly to newly acquired infections— 
that is, only active (as opposed to latent) infections confer a risk of 
progression to precancer, and the critical determinant of progression is 
whether the infection persists at a detectable level or whether a wom-
an’s immune system is able to regain control of it.(Hammer et al., 2020) 
This hypothesis is supported by evidence from the KPNC/PaP study 
cohort (in which the incidence of CIN2+ or CIN3+ following a newly 
detected HPV infection was similar or lower in older women compared 
to younger women)(Gage et al., 2015) and from the Guanacaste Natural 
History Study (which demonstrated that women with re-appearance of 
type-specific infections following two or more negative HPV tests had a 
very low risk of CIN2+).(Rodriguez et al., 2012) By assuming (consistent 
with the evidence) that reactivated infections in older women behave no 
worse than newly acquired infections, we avoid the need to model dif-
ferential progression risks for newly acquired versus reactivated in-
fections when screening is being evaluated. Instead we model HPV 
appearance, which includes both newly acquired and reactivated in-
fections, and can be measured when a woman shifts from a negative to a 
positive HPV result on a validated assay; the time clock determining the 
risks of disappearance and progression starts at the time of appearance, 
whether or not a woman has been infected with this type before. Given 
that vaccine trials in women over age 25 years have been underpowered 
to examine vaccine effectiveness in older women with evidence of past 
HPV exposure,(Castellsague et al., 2011; Wheeler et al., 2016) health 
decision models may not be able to reliably evaluate vaccination in older 
women unless new data become available. 
7.2. The risk of invasion 
The risk of invasion remains the most uncertain transition in cervical 
carcinogenesis, and it cannot be directly estimated. Modeling the risk of 
invasion requires estimating the duration of precancer in the absence of 
intervention— the so-called “dwell time”. As modern clinical studies 
censor women upon the development of CIN2/3, the transition risk from 
precancer to cancer cannot be observed for ethical reasons. A retro-
spective study from New Zealand analyzed historical data of women 
with typically large, long-standing cases of CIN3 (average age of 39) that 
were followed unethically many years ago,(McCredie et al., 2008) but 
the implied dwell time is underestimated because it is not clear how long 
lesions were present prior to the beginning of follow-up. Below we 
address methods for indirect estimation of this and other uncertain 
transition risks in the proposed models. 
8. Calibrate uncertain transitions 
In the absence of direct estimates, we rely on model fitting tech-
niques known as calibration to infer values for uncertain transitions. As 
described above, the risk of invasion remains uncertain; additionally, 
HPV appearance risks may vary considerably between populations, as 
sexual behavior patterns differ. Once natural history model transitions 
have been directly estimated to the extent that available data allow (e.g., 
risks of HPV disappearance and progression to precancer, which we 
assume as a necessary simplification are consistent within each of the 
Lower HPV Prevalence, Higher HPV Prevalence, and HIV Models), sta-
tistical methods can be used to explore values for uncertain transitions 
(e.g., risks of appearance, invasion) (Fig. 4A, B). The goal of calibration 
is to hone in on values for the uncertain transitions that are consistent 
with both the data-driven transition risks and empirical data on, for 
example, type-specific HPV prevalence in a population (considering age 
and cohort effects); distribution of HPV types in precancer and cancer; 
and incidence of invasive cancer (considering age and period effects). A 
strength of the proposed framework is that it focuses on direct estima-
tion (rather than calibration) for most transitions. With fewer unknown 
transitions, the model is less vulnerable to non-identifiability (i.e., 
different combinations of transition values can fit the same empirical 
data), which can weaken the utility of health decision analysis. 
9. Summary of main differences between the proposed and 
current natural history models 
Existing health decision models of HPV infection and cervical 
carcinogenesis have been instrumental in evaluating the shift from 
cytology-based screening to HPV testing— starting with HPV triage of 
ASC-US (or equivocal cytology) rather than repeat cytology,(Kim et al., 
2002) and now moving to primary screening.(Jansen et al., 2020; Kim 
et al., 2018) The earliest models defined precancerous health states 
using cytologic classifications (e.g., LSIL, HSIL)(Goldie et al., 1999; 
Kulasingam et al., 2006; Myers et al., 2000); later models shifted to-
wards histologic classifications (i.e., CIN1, CIN2, CIN3).(Burger et al., 
2020; Jansen et al., 2020; Messoudi et al., 2019; Vanni et al., 2011) One 
published model (developed by several authors of this paper) initiated 
the removal of CIN1 as a health state on the causal pathway and also 
implemented time-dependent transition risks.(Campos et al., 2014) The 
proposed framework relies on these fundamental changes, as well as 
others described in Table 2. In order to project the performance of new 
technologies that can identify a transforming infection with increasing 
accuracy, microsimulation models will need to define precancer more 
rigorously than at present; to evaluate prevention strategies (i.e., age, 
screening interval, screening test), transitions must reflect time-in-state. 
9.1. Shifting away from health states defined by histopathology 
The move away from the CIN scale might be seen as controversial but 
it is important. Most health decision models still require sequential 
progression through separate health states for CIN1 (mild dysplasia), 
CIN2 (moderate dysplasia), and CIN3 (severe dysplasia and carcinoma 
in situ) prior to cervical cancer. However, there is strong evidence 
against the reproducibility and biologic meaning of this three-part 
diagnostic scoring and its inventor long ago abandoned it.(Richart, 
1990) While considered a reference standard of diagnosis, histopathol-
ogy results depend on the placement of colposcopically-directed biopsy, 
and typically only the most visible lesion(s) are sampled. The categories 
are not reproducible.(Stoler and Schiffman, 2001) CIN1 is merely an 
inaccurate indication of HPV infection, rather than a necessary and 
measurable stage on the causal pathway to cervical cancer.(Cox et al., 
2003) CIN2 is a heterogeneous classification— while some will even-
tually invade, many will regress over time.(Tainio et al., 2018) Efforts to 
divide CIN2 into low-grade and high-grade lesions based on immuno-
histochemical staining of p16, a progression-related biomarker (i.e., the 
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Lower Anogenital Squamous Terminology [LAST] classification system), 
have proved inadequate, with many lesions staining positive without 
evidence of precancer.(Castle et al., 2020) Even reliance on the stricter 
histologic classification of CIN3/AIS as a surrogate for precancer may 
lead to some misspecification of invasive potential, because several 
hrHPV types (e.g., HPV51) are commonly found in CIN3/AIS but very 
rarely in invasive cancers.(Demarco et al., 2020; Smith et al., 2007) 
In short, we argue that while histopathologic CIN2 or CIN3 or his-
tologic HSIL or AIS taken alone are potential markers of precancer, these 
are neither sufficiently reproducible nor specific to represent discrete 
and necessary health states on the causal pathway. Acknowledging that 
precancer cannot be perfectly discriminated, we aim to rely on com-
posite measures, including both molecular and morphological end-
points, to estimate this health state in the proposed natural history 
model. The ideal would be to avoid identifying precancer too narrowly 
(missing some lesions at high risk of invasion) or too broadly (including 
lesions that are not likely to invade). Important predictors of lesion 
severity, to be used in combination as available with histology, include 
restriction to lesions associated with definitely carcinogenic HPV types 
and known duration of infection. At present, we will define precancer as 
a reference pathology diagnosis of CIN2 or CIN3 or a LAST system HSIL 
that is accompanied by at least one of the 13 hrHPV types. Requiring 
reference pathology standards and genotyping to define precancer re-
stricts the primary data sources that can be used to develop the natural 
history model, but allows the model to more accurately assess the 
enhanced predictive value of forthcoming biomarker assays, some of 
which will eventually be better at identifying precancer than the current 
CIN scale. As novel biomarkers with improved predictive value are 
validated and available from longitudinal data sets, these could be 
incorporated into the modeling framework’s definition of precancer (e. 
g., the size of the lesion as a measure of duration of precancer, detection 
of over-expression of HPV E6 and E7 oncoproteins, viral/host DNA 
methylation and integration). 
9.2. Transitions based on time-in-state 
Another difference in the proposed model (relative to most earlier 
generations of health decision models) is the assumption that transitions 
Fig. 4. Direct estimation versus calibration of transition probabilities. 
In the Lower HPV Prevalence Model (A), data are available to directly estimate transition risks for disappearance and progression from longitudinal studies. We assume 
these risks are consistent across Lower HPV Prevalence populations. The transition risks for appearance vary according to sexual behavior in a population, and can 
only be directly estimated when population-based longitudinal data are available. Thus, in most cases, the risk of appearance is calibrated to fit HPV prevalence (by 
genotype and age) while using direct estimates for disappearance. We will explore the impact of individual-level frailty and how it may impact clustering of infections 
appearing within a woman (due to sexual behavior or immune factors). We assume the risk of disappearance is the same whether an infection was newly acquired or 
reactivated. 
In the Higher HPV Prevalence Model (B), data will soon be available from longitudinal studies to directly estimate transition risks for disappearance. We assume these 
risks are consistent across Higher HPV Prevalence populations with a low burden of HIV. As in Lower HPV Prevalence settings, direct estimates for the risk of 
appearance are rarely available, so this transition risk will be calibrated to fit HPV prevalence while using direct estimates for disappearance. Due to limited data, 
direct estimates for progression risks in Higher HPV Prevalence settings are not available. We are exploring the relationship between the prevalence of precancer 
among women with hrHPV in Lower and Higher HPV prevalence settings to determine whether progression risks (conditional on hrHPV infection) are similar to 
Lower HPV Prevalence settings or would need to be calibrated. 
In both the Lower and Higher HPV Prevalence models, the risk of invasion is unobserved for ethical reasons, and must be calibrated to fit cancer presentation data for 
squamous cell carcinoma and adenocarcinoma (by HPV genotype, age and stage at presentation prior to widespread screening). Whether the risk of invasion is 
initially calibrated in a Higher HPV Prevalence setting (where screening may be less widespread and HPV prevalence patterns may better reflect sexual behavior 
patterns among more recent cohorts) or a Lower HPV Prevalence setting (where more data are available to directly estimate progression risk and prevalence of 
precancer), we anticipate holding the risk of invasion constant between models, as we hypothesize that this transition does not change as a function of cell-mediated 
immunity. 
The HIV Model is not shown, as it is not yet clear which transition risks can be directly estimated versus calibrated. ADC: adenocarcinoma; SCC: squamous 
cell carcinoma. 
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Table 2 
Summary of main differences between the proposed and current natural history 
models of HPV infection and cervical carcinogenesis.a  
Model feature Existing models Proposed modeling 
framework 
Health states Normal cervix 
HPV infection 
Immuneb 
CIN1, CIN2, CIN3 
Cervical cancer  
Pros:   
• Histologic diagnoses 
correspond to existing 
clinical action thresholds 
(i.e. , treating CIN2+).  
• Evidence supports 
reduced likelihood of 
type-specific re-infection 
(immunity).  
Cons:   
• Histologic diagnoses are 
not reproducible and may 
be inconsistent across 
studies.  
• CIN1–2-3 transitions do 
not reflect the causal 
pathway and lead to non- 
identifiability issues in 
transitions.  
• Data are unavailable to 
specify the probability, 
duration, and potential 
waning of natural 





Cervical cancer  
Pros:   
• Health states are 
parsimonious and align with 
the causal pathway of 
cervical carcinogenesis.  
• The precancer state is 
rigorously defined to allow 
for more accurate 
evaluations of novel 
biomarkers.  
• The definition of precancer 
can be further refined as 
more biomarker data 
become available.  
Cons:   
• Transitions require intensive 
statistical analysis of 
prospective data sources 
with reference diagnoses of 
precancer. 
Corollary transitions HPV acquisition 
HPV clearance (with or 
without immunityb) 
HPV progression/ 
regression to/from CIN1, 
CIN2, CIN3 
Invasion  
Pros:   
• Transitions can be 
derived from the 
literature and clinical 
data.  
Cons:   






Pros:   
• Transitions explicitly 
consider the possibility of 
latency and reactivation.  
Cons:   
• Withf ewertransition 
probabilities available for 
calibration, model fitting 
to empirical data may be 
more difficult . 
Variables that modify 
transitions 
HPV acquisition: Age, 
HPV type, history of prior 
type-specific infectionb 
HPV clearance: Age, HPV 
type 
HPV progression/ 
regression: Age, HPV type 
Invasion: Age, HPV type  
Stratified models for: 
WLHIV  
Pros:   
• Models can be adapted to 
fit most populations 
through the calibration 
process.  
Cons:   
• The age of a woman is an 
imperfect proxy for the 
age of an infection. 
HPV appearance: Age, HPV 
type 
HPV disappearance: Time 
since infection 
HPV progression: HPV type, 
time since infection 
Invasion: HPV type, time 
since infection/duration of 
precancer  
Stratified models for: 
Lower HPV prevalence 
setting 
Higher HPV prevalence 
setting 
WLHIV  
Pros:   
• Model transitions consider 
time-in-state, discerning the 
differential impact of new 
and old infections in older 
women.  
Table 2 (continued ) 
Model feature Existing models Proposed modeling 
framework  
• Markov models may face 
challenges incorporating 
time-in-state transitions 
across health states.  
• HPV clearance does not 
vary by HPV type, but 
progression does. 
(Demarco et al., 2020)  
• Models calibrated to High 
HPV Prevalence settings 
may not reflect potential 
differences in HPV- 
related transitions in 
populations with reduced 
cell-mediated immunity.  
• Models will reflect 
differences in HPV 
clearance and progression 
between populations, if 
these exist.  
Cons:   
• Models require prospective 
longitudinal data 
fromHigher HPV 
Prevalence settings.  
• Microsimulation models 
may be required to 
incorporate transitions that 
vary by time-in-state; model 
development and data 
requirements are intense. 
Direct estimation of 
transition 
probabilitiesc 
Varies by model  
Pros:   
• Fewer longitudinal data 
sources are needed, as 
uncertain transitions 
can be calibrated.  
Cons:   
• Transitions between 
CIN states will vary 
widely between studies. 
HPV appearance (when data 
available) 
HPV disappearance 
HPV progression (Lower 
HPV Prevalence setting)  
Data sources: 
Guanacaste Natural History 
Study, Costa Rica Vaccine 
Trial and Long-Term Follow- 
Up Study, ALTS (Lower HPV 
Prevalence Model) 
ACCME Cohort, Project Itoju 
(Higher HPV Prevalence 
Model)  
Pros:   
• Models will consider 
potentially different 
transitions inHigher HPV 
Prevalence settings .  
Cons:   
• Data sources inHigher HPV 







Estimation of most 
transitions requires some 
use of model-fitting 
techniques  
Pros:   
• Models can be adapted to 
fit a wide range of 
populations.  
Cons:   
• Over-reliance on 
calibration techniques 
leads to non- 
identifiability issues that 




HPV appearance (when data 
unavailable) 
HPV progression (Higher 
HPV Prevalence settings) 
Invasion  
Pros:   
• Fewer transitions open to 
calibration can lead to 
identifiable models that 
better reflect the natural 
history of disease.  
• Models are more 
parsimonious and 
transparent.  
Cons:   
• Data requirements are 
intensive.  
a HPV: Human papillomavirus; CIN: Cervical intraepithelial neoplasia (grade 
1, 2, or 3); WLHIV: Women living with HIV. 
b “Immune” refers to a reduced risk of HPV type-specific re-infection. Existing 
models typically include either a separate immune health state or a reduced 
likelihood of repeat acquisition with the same type. 
c Data on HPV transition risks for WLHIV, as a function of immune and anti-
retroviral therapy status, are very limited. The HIV model deserves thorough 
consideration that is beyond the scope of this paper. 
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from the HPV-infected state rely profoundly on duration— that is, the 
longer an infection actively persists, the less likely it is to clear and the 
more likely it is to have progressed (Ho et al., 1998). Invasion also relies 
on duration but with a more linear transition probability. Other health 
decision models have typically based these transitions on age— 
assuming that as women age, the risks of viral persistence and pro-
gression tend to increase. We suggest that these age-based HPV risks are 
combining two different groups of infection in older women: 1) persis-
tent infections that have been present for years (often these infections 
are prevalently detected at baseline in long-term follow-up studies); and 
2) newer appearing infections (either newly acquired or “reactivated” 
due to loss of immune control). Newly appearing infections at any age of 
a woman are associated with lower risk than persistent ones.(Hammer 
et al., 2020) By averaging transition risks for these two different groups, 
models using age-based clearance and progression risks will likely un-
derestimate the risk of longstanding prevalent infections and over-
estimate the risk of newly appearing infections in older women. Thus, 
these models likely overestimate the median age at which cancer- 
causing HPV infections are acquired, thus overestimating the benefits 
of vaccination at older ages. To compensate for later age at acquiring the 
causal infection, these models must speed the risks of progression and 
invasion to achieve model fit to cancer incidence targets, thus yielding 
potentially erroneous policy conclusions regarding the length of 
screening intervals for primary HPV testing.(Burger et al., 2020) By 
estimating transition risks by duration of infection and rigorously 
defining precancer, the proposed model can reflect the differential risk 
of precancer among women with persistent versus newly appearing 
infections. 
10. Conclusions 
We present a new health decision modeling framework that is 
aligned with the multi-stage causal pathway to cervical cancer. We 
argue that the model health states (i.e., normal cervix, HPV infection, 
precancer, and cancer) and corollary transitions (i.e., appearance, 
disappearance, progression, and invasion) apply universally across all 
populations. However, the risks of transitioning between health states 
likely differ, as evidenced by variation in HPV prevalence patterns 
attributable to cell-mediated immunity. We argue that direct estimates of 
HPV-type specific transition probabilities are available to inform more 
natural history transitions than existing models currently use. It will be 
critical to determine whether HPV transition risks vary by population 
based on cell-mediated immunity, necessitating at least two natural 
history models for HIV-negative women. 
The proposed microsimulation modeling framework will be well- 
suited to address complex cervical screening and triage algorithms, 
including novel biomarker tests. It will also be able to estimate the direct 
benefits associated with HPV vaccination strategies. However, we 
acknowledge that a variety of modeling approaches are useful. Further 
work will be needed to develop companion dynamic models of HPV 
transmission consistent with the proposed framework to estimate the 
indirect benefits (i.e., herd immunity) of vaccination strategies; these 
models will likely rely on calibration to a greater extent than the 
microsimulation model we propose here. Disadvantages of the proposed 
microsimulation framework are the resource requirements for devel-
opment— both time and data needs are intensive. However, once 
microsimulation models evolve to have greater fidelity to the natural 
history, we expect they will be better able to inform simpler and more 
accessible modeling approaches with fewer data needs. 
We are working actively with colleagues who work in lower- 
prevalence settings to validate this model; in higher-prevalence pop-
ulations to fill in remaining data gaps among populations with the 
greatest burden of cervical cancer; and among WLHIV to gather data on 
the fundamental effectiveness of prevention strategies. We invite dis-
cussion and challenges to our approach. Our goal is to elevate the 
perceived quality of evidence from microsimulation models so that these 
tools can be used with maximum achievable confidence to inform effi-
cient use of resources and achieve global cervical cancer control. 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.ypmed.2021.106438. 
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